Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol-13: Issue 8
Open Access

Ancient Insights, Modern Microbes: Siddha Contributions to Gut Microbiome Medicine

Neethiraja M[1], D. Velaman[2], Saravanasingh karan chand mohan singh[3]*, S. Dinesh[4], M.N. Parandhaman[5], C. Vimala[6], V. Sathiya[7], A. Jayakalaiarasi[8], C. Devaraj[9], S. Paechiyammal[10] , Senthilvel. G[11]

1. Senior project associate, CSIR-TKDL, Adyar, Chennai-20
2. Assistant professor, Department of Gunapadam - (Marunthakaviyal), Sudha saseendran siddha medical college and hospital, Kaliyakavilai, Kanyakumari 629153
3. Assistant Professor, Department of Maruthuvam, National Institute of Siddha, Ministry of AYUSH, Govt of India, Tambaram sanatorium, Chennai-47
4. Senior project associate, CSIR-TKDL, Adyar, Chennai-20
5. Reader, Dept of aruvai thol maruthuvam, JSA Medical College for Siddha and Research Centre, Ulundurpet, Kallakurichi –606104.
6. Associate professor, Department of Noi Anuga Vidhi Ozhukkam, Maria Siddha Medical College, Moovattumugam, Attoor, Kanyakumari Dist
7. Associate professor, Department of udal koorugal, JSA siddha medical college & research centre, Pali, ulundhurpet_606104.
8. Associate Professor, Department of forensic medicine and toxicology, Santhigiri siddha medical college and research organization, Trivandrum, kerala-6955892.
9. Associate Professor, Department of Dravya Guna Vijnana, Maria Ayurveda Medical College, Attor, Kanyakumari Dist
10. Resident Medical Officer, National institute of Siddha, Ministry of AYUSH, Govt of India, Tambaram sanatorium, chennai-47
11. Director (i/c), Professor & HOD, Department of Gunapadam, National Institute of Siddha, Ministry of AYUSH, Govt. of India, Chennai – 600 047

***Corresponding Author:**
Dr. Saravanasingh Karan Chand Mohan Singh, M.D (Siddha), Ph.D.
Assistant professor,
Department of Maruthuvam,
National Institute of Siddha, Chennai-47
E. Mail: k.saravanasingh@gmail.com

Cite this paper as: Neethiraja M, D. Velaman, Saravanasingh karan chand mohan singh, S. Dinesh, M.N. Parandhaman, C. Vimala, V. Sathiya, A. Jayakalaiarasi, C. Devaraj, S. Paechiyammal, Senthilvel. G (2024). Ancient Insights, Modern Microbes: Siddha Contributions to Gut Microbiome Medicine. Frontiers in Health Informatics, Vol. 13, No.8, 7507-7528

Abstract

The gut microbiome plays a vital role in our health, influencing everything from how our bodies function to our metabolism and immune system. Thanks to advances in sequencing technologies, we now understand just how complex the communities of microbes in our digestive system are and how closely they relate to our overall well-being. When the balance of these microbes is disrupted—a condition known as dysbiosis—it can lead to various health

issues, including metabolic disorders, inflammatory diseases, and even mental health problems. Interestingly, traditional medical systems like Siddha medicine from India have long emphasized the importance of digestive balance and the use of plant-based remedies to support health. Recent research shows that herbal medicines, especially those packed with polyphenols, fibers, and alkaloids, can positively influence microbiomes by promoting the growth of beneficial microbes. In this review, we explore the latest findings on the gut microbiome, insights from herbal medicine research, and the philosophical and medical context of the Siddha system. We conducted a thorough analysis of 40 peer-reviewed studies to bridge modern biomedical knowledge with Siddha practices. Our findings indicate that Siddha herbs such as Terminalia chebula, Piper longum, Phyllanthus emblica, and various Kudineer formulations can help relieve digestive issues and may also improve the health of our gut microbiome. We also discuss the molecular mechanisms behind these effects, the challenges in validating these findings, and the exciting potential for developing integrated care models.
Key words: Gut microbiome, Health Metabolism, Immune system, Sequencing technologies, Microbial communities, Dysbiosis, Siddha medicine

1. Introduction

The human gastrointestinal tract harbors trillions of microorganisms, collectively referred to as the gut microbiome, encompassing bacteria, archaea, viruses, and eukaryotic microbes (Thursby & Juge, 2017). These microbial communities encode millions of genes that substantially expand the metabolic and immunological capacity of the host (Qin et al., 2010). The symbiotic relationship maintained by the host and its microbiota is central to nutrient absorption, energy balance, immune maturation, and neuromodulation. Conversely, perturbations in microbial diversity or abundance—termed dysbiosis—are strongly linked to pathophysiological states including obesity, type 2 diabetes, inflammatory bowel disease, colorectal cancer, and even depression and anxiety (Cani & Jordan, 2018).

Despite rapid advances, therapeutic strategies aimed solely at microbiota remain limited, with probiotics and dietary fibers providing partial benefits. Traditional medicinal systems, however, have long recognized the centrality of digestion and gut balance to systemic well-being. Siddha medicine, one of the oldest codified systems in India, rooted in Tamil culture, emphasizes the correction of disturbances in vatham (wind), pitham (bile), and kabham (phlegm)—the three fundamental humors (mukkuttram)—through personalized herbal, mineral, dietary, and lifestyle interventions (Srikanth et al., 2018).

Among its diverse therapeutic arsenal, plant-based formulations constitute a critical domain. The Siddha pharmacopoeia includes over 500 commonly used herbal drugs classified according to therapeutic properties such as chooranam (powders), kudineer (polyherbal decoctions), and lehiyam (medicated pastes) (Subbarayan & Thillaivanan, 2011). Many of these remedies, particularly those for gastrointestinal ailments, involve plants that modern pharmacological studies have shown to contain fibers, tannins, bioflavonoids, and alkaloids capable of altering the gut microbial environment (Pandey et al., 2013).

Recent multi-omics approaches—including 16S rRNA sequencing, shotgun metagenomics, transcriptomics, and metabolomics—have uncovered mechanistic insights into how phytochemicals from herbal drugs interact with the gut microbiome (Liang et al., 2022). Polyphenols, for example, exhibit limited absorption in the upper gut but undergo extensive

metabolism by colonic bacteria into bioactive metabolites such as short-chain fatty acids (SCFAs), phenolic acids, and urolithins, which in turn influence host immunity and metabolic homeostasis (Selma et al., 2009). Certain herbal polysaccharides act as prebiotics by selectively nourishing beneficial genera such as Bifidobacterium and Lactobacillus (Zhang et al., 2016). Conversely, gut microbial enzymes can biotransform inert plant glycosides into pharmacologically active compounds, highlighting the bidirectional nature of host–herb–microbe interactions.

The rationale of this review is threefold. First, to synthesize the expanding body of research on microbiome modulation through herbal medicine, thereby grounding traditional Siddha prescriptions in modern scientific understanding. Second, to analyze current evidence specific to Siddha pharmacology and its relevance to gut health, including single herbs like Terminalia chebula (Kadukkai) and integrative polyherbal formulations. Third, to chart out opportunities and challenges in integrating Siddha-based approaches into mainstream microbiome research and personalized healthcare. By drawing upon 40 peer-reviewed articles across biomedical databases and AYUSH repositories, this review aims to present a holistic narrative enhancing the scientific credibility of Siddha medicine in the global context of microbiome science.

2. Methodology of Literature Review

2.1 Design of the Review

This literature review was conducted using a narrative and systematic hybrid approach, aiming to synthesize available evidence on the gut microbiome, herbal medicine, and specifically the Siddha system. Unlike systematic reviews that restrict inclusion to tightly defined randomized controlled trials, this review intentionally incorporated preclinical, clinical, and ethnopharmacological studies to capture both biomedical findings and traditional perspectives. The guiding question was: How does Siddha and herbal medicine modulate the gut microbiome, and what evidence supports its therapeutic relevance in health and disease?

2.2 Information Sources

Relevant sources were searched between January 2000 and June 2024 across multiple scholarly and institutional databases, including biomedical databases such as PubMed, Scopus, Web of Science, and ScienceDirect. Additionally, ethnomedical repositories were consulted, including the AYUSH Research Portal (Government of India), Digital Repository of Indian Medicinal Plants, and Shodhganga dissertations. Grey literature sources such as conference proceedings, theses, and selected Siddha classical texts translated into English were also included. These platforms were chosen to ensure coverage of both modern microbiome research and traditional medicine studies often excluded from mainstream databases.

2.3 Search Strategy

Boolean combinations of keywords were applied. Examples included "gut microbiome" AND "herbal medicine", "gut flora" AND "polyphenols", "Siddha medicine" AND "microbiome", "Terminalia chebula" OR "Piper longum" AND "gut bacteria", and "polyherbal decoctions" AND "intestinal health". Where possible, Medical Subject Headings (MeSH) were used for precision, such as "Gastrointestinal Microbiome/drug effects".

2.4 Inclusion and Exclusion Criteria

Inclusion criteria encompassed peer-reviewed articles, reviews, theses, and clinical trials between 2000–2024, preclinical or clinical studies assessing the impact of herbs or Siddha formulations on gut microbial diversity, metabolites, or gastrointestinal conditions, and

conceptual or ethnopharmacological works linking Siddha theory to digestion or mukkuttram balance. Exclusion criteria included studies not addressing gut microbiota or host–microbe interactions, articles without primary data or critical review (such as newspaper articles or non-scientific blogs), and reports lacking adequate methodological transparency.

2.5 Selection Process

A total of 120 documents were initially identified. After removing duplicates and applying exclusion criteria, 40 studies were selected for detailed analysis. Among these, 18 focused on gut microbiome and herbal medicine with a general, global scope, 12 were Siddha or Indian ethnomedicine-specific, 6 discussed molecular mechanisms of phytochemical–microbiota interaction, and 4 were review or meta-analysis papers offering integrative frameworks. This blend allowed for triangulation of evidence—from high-rigor biomedical research to contextually relevant ethnomedical literature.

2.6 Data Extraction and Thematic Synthesis

For each selected study, the following information was charted: author(s), year, study design, intervention/herb studied, microbiota outcomes, clinical/disease outcomes, and relevance to Siddha concepts. These were then grouped into thematic categories corresponding to subsequent sections of this review: microbiome in health and disease, herbal modulation, Siddha conceptual framework, and evidence from interventions.

A narrative synthesis method was adopted, whereby findings were summarized under themes and critically analyzed for convergence, inconsistencies, and methodological quality. Clinical significance was assessed in terms of study populations, sample sizes, effect sizes, and reproducibility. Preclinical animal data were carefully contextualized and not over-generalized to human outcomes.

2.7 Limitations of the Review Approach

The methodology had inherent limitations. First, the literature base on Siddha medicine and microbiome interactions is still sparse compared to Ayurveda or Chinese medicine, and several references were drawn from related herbal pharmacology rather than strictly Siddha trials. Second, variability in study designs—ranging from in vitro fermentation to clinical pilot studies—limited direct comparability. Third, some potentially relevant work in Tamil or unpublished government reports may not have been accessible to this review due to language and availability constraints.

Despite these limitations, the methodological strategy provided a comprehensive, balanced, and multidisciplinary dataset, enabling the construction of a robust narrative connecting Siddha principles to modern microbiome science. The transparency in inclusion and synthesis strengthens the review's academic credibility while honoring the integrative nature of the subject.

3. Gut Microbiome and Human Health

3.1 Overview of the Gut Microbial Ecosystem

The human gastrointestinal tract is home to an estimated 100 trillion microbial cells, outnumbering human cells by roughly a factor of one to one, and encoding a gene pool at least 150 times larger than that of the host (Qin et al., 2010). These microbes are unevenly distributed: the stomach and proximal small intestine harbor relatively low biomass due to acidic pH and bile acids, while the colon represents the densest microbial ecosystem on earth, containing over 10^{11}–10^{12} organisms per gram of luminal content (Sekirov et al., 2010).

Dominant bacterial phyla include Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. Within these, genera such as Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, Akkermansia, and Faecalibacterium play critical roles in digestion, energy harvest, and immune modulation (Thursby & Juge, 2017). The stability of these communities is influenced by diet, age, genetics, environment, and medication use.

3.2 Core Functions of the Microbiome

3.2.1 Nutrient Metabolism

Gut microbes metabolize complex carbohydrates, resistant starches, and fibers into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. SCFAs provide 5–10% of total caloric intake, regulate glucose and lipid metabolism, enhance intestinal barrier function, and modulate satiety signaling (Koh et al., 2016).

3.2.2 Immune System Modulation

The microbiome influences both innate and adaptive immunity. Commensals stimulate the development of gut-associated lymphoid tissues and induce regulatory T cells critical for preventing autoimmunity (Belkaid & Hand, 2014). Dysregulated microbiota can promote systemic inflammation by altering the balance of anti- and pro-inflammatory cytokines.

3.2.3 Protection Against Pathogens

Competition for nutrients and ecological niches allows commensals to act as a barrier against colonization by pathogens. Certain strains produce bacteriocins or lower gut pH through SCFA production, inhibiting harmful bacteria such as Clostridioides difficile (Buffie & Pamer, 2013).

3.2.4 Neurological and Endocrine Links

The gut–brain axis describes bidirectional communication mediated by vagal nerve pathways, neuroactive metabolites (such as GABA and serotonin), and microbial modulation of hypothalamic–pituitary–adrenal axis activity (Mayer et al., 2015). This has profound implications for psychiatric and neurodegenerative disorders.

3.3 Dysbiosis and Its Health Implications

Changes in microbial richness and diversity, termed dysbiosis, are associated with a spectrum of diseases. Typical dysbiosis patterns include reduced abundance of butyrate producers (Faecalibacterium prausnitzii) and loss of mucus-associated bacteria (Akkermansia muciniphila), alongside expansion of potentially pathogenic Proteobacteria (Shreiner et al., 2015).

In metabolic disorders, elevated Firmicutes-to-Bacteroidetes ratios correlate with obesity by enhancing calorie extraction from dietary polysaccharides (Turnbaugh et al., 2006). Reduced microbial diversity is also linked to insulin resistance and systemic inflammation contributing to type 2 diabetes (Larsen et al., 2010). For gastrointestinal conditions, depletion of protective bacteria and overgrowth of pathobionts are features of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Microbiota-targeted treatments like fecal microbiota transplantation (FMT) are being explored (Paramsothy et al., 2017). In cancer, dysbiosis leading to increased genotoxic metabolites and secondary bile acids can promote colorectal carcinogenesis (Arthur et al., 2012). For neuropsychiatric disorders, altered microbiota compositions are observed in autism spectrum disorders, depression, and Parkinson's disease, suggesting far-reaching systemic consequences (Cheung et al., 2019).

3.4 Determinants of Microbiome Composition

3.4.1 Diet

Diet is the strongest modulator of microbiome structure. High-fiber, plant-based diets encourage SCFA producers and beneficial bacterial diversity, while Westernized diets rich in fat, sugar, and animal protein promote dysbiosis (David et al., 2014). This direct nutritional link underscores why traditional medicine systems that emphasize dietary balance may influence microbial communities.

3.4.2 Mode of Birth and Early Life

Infants delivered vaginally acquire maternal Lactobacillus and Bifidobacterium, while Cesarean-born infants are more colonized by skin-associated microbes, potentially affecting immune maturation (Dominguez-Bello et al., 2010). Breastfeeding provides oligosaccharides that act as prebiotics.

3.4.3 Medications

Antibiotics, proton pump inhibitors, and non-steroidal anti-inflammatory drugs perturb microbial ecosystems, reducing resilience. Repeated early-life antibiotic exposure is associated with long-term risks of asthma, obesity, and allergies (Cox & Blaser, 2015).

3.4.4 Genetics and Environment

Although host genetics influence factors such as mucin glycosylation patterns supporting gut microbes, environmental exposures—including geography, sanitation, and cultural dietary practices—often have stronger effects (Spor et al., 2011).

3.5 Microbiome as a Therapeutic Target

Conventional strategies to manipulate the gut microbiota include probiotics (administration of live beneficial strains such as Lactobacillus and Bifidobacterium, though evidence is modest and strain-specific), prebiotics (non-digestible food ingredients like inulin and fructooligosaccharides that selectively promote beneficial bacteria), synbiotics (combination of probiotics and prebiotics), and fecal microbiota transplantation (FMT), which is effective for recurrent C. difficile infections, though concerns about safety and reproducibility remain.

While these approaches are being tested for a range of chronic diseases, gaps remain regarding long-term efficacy, personalization, and mechanistic clarity. This creates a fertile avenue for evaluating herbal medicine, which has long been implicated in digestive health but is only recently studied through the lens of the microbiome.

3.6 Relevance to Siddha and Herbal Systems

The burgeoning evidence linking diet, herbs, and microbiome health resonates with Siddha tenets that view digestion as central to systemic balance. Traditional classifications of herbs by taste (suvai), potency (veeryam), and post-digestive effect (pirivu) parallel modern recognition that phytochemicals undergo transformations in the gut, yielding metabolites with systemic roles. Herbs traditionally used for conditions such as vali azhal keel vayu (inflammatory bowel disorders) may exert their effects via microbiome-mediated modulation.

By situating Siddha knowledge within modern microbiome science, we begin to unravel how traditional practices anticipated, albeit via different epistemologies, the centrality of gut ecology to human health.

4. Herbal Medicine and Microbiome Interactions

4.1 Introduction

For centuries, herbal medicines have been at the core of traditional health systems. Their therapeutic benefits were attributed to balancing humor, detoxifying the body, and strengthening vitality. Only in recent decades has modern science begun to unravel that a major

mediator of herbal effects lies in their ability to interact with and modulate the gut microbiome. Herbs contain diverse bioactive compounds—polyphenols, alkaloids, saponins, polysaccharides—that undergo microbial metabolism to yield bioactive metabolites, while also shaping the microbial community itself (Liang et al., 2022). This bidirectional interaction represents a key convergence point of traditional wisdom and modern microbiology.

4.2 Mechanisms of Interaction

4.2.1 Modulation of Microbial Composition

Herbal extracts influence community structure by promoting beneficial microbes (such as Bifidobacterium and Lactobacillus) while suppressing potentially harmful ones (Lv et al., 2019). For instance, polyphenol-rich plants often reduce Enterobacteriaceae proliferation while enhancing SCFA-producers, leading to improved gut barrier function.

4.2.2 Biotransformation of Phytochemicals

Many plant compounds exhibit low bioavailability in their original form. Gut microbes hydrolyze glycosides, deconjugate polyphenols, or ferment fibers to generate smaller molecules with enhanced biological activity. For example, ellagitannins from Phyllanthus emblica are converted into urolithins, potent anti-inflammatory metabolites (Selma et al., 2009).

4.2.3 Production of Beneficial Metabolites

Microbes fed by herbal fibers and polysaccharides produce SCFAs that nourish colonocytes, regulate immunity, and provide systemic metabolic benefits. Herbs act as prebiotics, enhancing metabolic flexibility of the host.

4.2.4 Antimicrobial and Selective Pressure

Certain phytochemicals, such as alkaloids and essential oils, exert antimicrobial activity. Rather than broad destruction, many act selectively, suppressing pathogens while sparing commensals, thereby reshaping the microbiota towards a balanced state (Wang et al., 2019).

4.3 Insights from Global Herbal Medicine Traditions

4.3.1 Traditional Chinese Medicine (TCM)

TCM formulations like Huangqin Tang have shown efficacy in ulcerative colitis through modulation of gut flora and SCFA production (Feng et al., 2019). Berberine, a common alkaloid in TCM herbs, exerts lipid-lowering and anti-diabetic effects partly by restructuring gut microbial communities (Zhang et al., 2012). These findings illustrate how complex herbal formulas can exert systemic influence through microbiome–metabolite interactions.

4.3.2 Ayurveda

Ayurveda, closely related to Siddha, prescribes decoctions (kashayam) and powders (chooranam) for digestive disorders. Herbs such as Triphala—a combination of Emblica officinalis, Terminalia chebula, and Terminalia bellirica—have been shown to enhance abundance of Bifidobacteria and Lactobacillus, while suppressing enteric pathogens and reducing colonic inflammation in preclinical models (Peterson et al., 2019).

4.4 Siddha and Indian Herbal Evidence

4.4.1 Terminalia chebula (Kadukkai)

Widely regarded as a "king of medicines" in Siddha texts, Kadukkai is prescribed for digestive complaints and detoxification. Modern studies indicate that T. chebula tannins act as substrates for gut microbes, stimulating butyrate production and inhibiting growth of ulcer-inducing pathogens such as Helicobacter pylori (Sharma et al., 2010).

4.4.2 Piper longum (Thippili)

Traditionally used to enhance appetite and relieve respiratory and gastrointestinal ailments, P. longum contains piperine, which has antimicrobial activity and can enhance microbiota-mediated absorption of other compounds. Animal studies highlight its role in modulating intestinal flora and improving gut barrier integrity under conditions of induced colitis (Bhardwaj et al., 2020).

4.4.3 Phyllanthus emblica (Nellikkai)

Rich in vitamin C and tannins, this fruit is central to Siddha formulations for digestion, rejuvenation, and immunity. Its polyphenols undergo microbial transformation into urolithins with anti-inflammatory and anti-aging potential. Studies suggest it promotes Lactobacillus spp. while reducing oxidative stress markers (Baliga & Dsouza, 2011).

4.4.4 Polyherbal Decoctions (Kudineer)

Siddha recommends Kudineer chooranam formulations—polyherbal decoctions targeting fevers, inflammation, and digestive imbalance. Though microbiome-focused research remains limited, bioinformatics predictions and phytochemical analyses suggest that the synergistic combination of herbs could select for beneficial microbial consortia while suppressing pathogens.

4.5 Clinical Relevance

Although clinical trials remain limited, the growing body of evidence suggests that herbal medicines may benefit patients by restoring balance in dysbiosis-related conditions such as IBS, IBD, or metabolic disorders, providing adjunct therapy alongside conventional treatments (such as reducing antibiotic-associated side effects), and offering personalized approaches by targeting humoral imbalances in Siddha while biologically reshaping microbiota profiles. Some Siddha herbs already demonstrate prebiotic effects comparable to standard nutraceutical supplements, positioning them as candidates for evidence-based phytobiotics.

4.6 Limitations of Current Evidence

Despite encouraging findings, several gaps remain. Most studies use animal models, with few robust human clinical trials. Dosages, preparation methods, and phytochemical concentrations vary significantly, affecting reproducibility. Microbiome outcomes are often reported as shifts in broad taxa, with limited functional insight into metabolic consequences. Siddha formulations are multi-component, complicating mechanistic attribution of observed changes. These limitations underscore the need for multidisciplinary collaboration, integrating pharmacognosy, microbiome science, and Siddha clinical expertise.

4.7 Summary

Herbal medicines act as both modulators and substrates of the human microbiome. While global traditions such as TCM and Ayurveda have contributed experimental data, the Siddha system presents a uniquely rich pharmacopeia awaiting rigorous microbiome-focused research. Early evidence with key herbs like T. chebula, P. longum, and P. emblica converges with Siddha's emphasis on digestive health, providing a promising foundation for integrative healthcare strategies.

5. Siddha System of Medicine: Concepts and Relevance

5.1 Historical and Philosophical Background

The Siddha system of medicine, emerging from the Dravidian cultural milieu of South India, is considered one of the oldest living codified healing traditions. Siddha teachings are attributed

to enlightened sages called Siddhars, who emphasized the interdependence of body, mind, environment, and cosmic forces (Subbarayan & Thillaivanan, 2011). Rooted in Tamil literature and philosophy, Siddha medicine shares similarities with Ayurveda but possesses its own unique pharmacological canon, diagnostic systems, and pharmacopoeia.

Central to Siddha thought is the doctrine of "Mukkuttram", referring to three regulatory humors: Vatham (air/wind), which governs movement, circulation, and nervous system activity; Pitham (bile/hot), which regulates metabolism, enzymatic processes, and heat; and Kabham (phlegm/cold), which maintains stability, lubrication, and immunity. Balance among these humors ensures good health, while their imbalance results in disease. Gastrointestinal health is particularly emphasized because digestion was viewed as the foundation of systemic equilibrium.

5.2 Siddha Concept of Digestion and Gut Health

Siddha texts describe the digestive fire (Agni) as a critical determinant of health. If digestion is weak or excessive, it leads to accumulation of toxins or undigested residues (Ama), predisposing to disease (Meenakshi et al., 2018). Although framed in pre-modern language, parallels can be drawn with the modern understanding of microbial fermentation, dysbiosis, and leaky gut syndromes.

For instance, imbalance of Vatham leads to bloating, abdominal pain, and irregular bowel habits (akin to IBS symptoms). Excess of Pitham results in acidity, gastritis, ulcers, and diarrhea (inflammatory gut pathology). Accumulation of Kabham causes sluggish digestion, mucus stools, and indigestion (low motility dysbiosis). Thus, Siddha's diagnostic framework resonates conceptually with patterns now explained by shifts in microbial composition and function.

5.3 Siddha Pharmacology (Gunapadam)

The Siddha pharmacopoeia is classified into herbal, mineral, metal-based, and animal-derived drugs, with herbal medicine forming the therapeutic backbone. The classic texts such as Agathiyar Gunapadam and Theraiyar Yemaga Venba meticulously describe herbs in terms of their taste (Suvai: sweet, sour, salty, pungent, bitter, astringent), potency (Veeryam: hot or cold effect post ingestion), and post-digestive effect (Pirivu: further refining the action on humors). This tripartite classification is strikingly analogous to modern pharmacokinetics where chemical transformations during digestion (including microbial metabolism) alter the bioactivity of phytoconstituents. A relevant example is Kadukkai (Terminalia chebula): described as bitter and astringent with balancing effect on all three humors. Modern research finds its hydrolyzable tannins, metabolized by colonic microbiota, generate gallic acid and butyrate-promoting activity—mechanistically explaining its digestive benefits.

5.4 Formulations for Gastrointestinal Disorders

Siddha formulary records numerous combinations for gut health. Kudineer (polyherbal decoctions) are prepared by boiling coarse powders of herbs in water and prescribed for fever, colitis-like conditions, and inflammatory disorders. Chooranam (powders) consist of single or compound drug powders mixed with honey or ghee, effective for indigestion, bloating, or constipation. Mathirai (pills) are processed plant/mineral formulations for long-term regulation of digestion. Lehyam (herbal electuaries) are semi-solid formulations enriched with sugar or jaggery, enhancing palatability and therapeutic synergy. These formulations were not only symptom-specific but humoral-corrective, aligning with the microbiome's ecological

restoration goal in modern approaches.

The common Siddha gastrointestinal formulations demonstrate probable microbiome relevance as detailed in the following analysis. Kudineer formulations, exemplified by Nilavembu kudineer and Aavarai kudineer, are traditionally indicated for fever and gut inflammation. Their possible microbiome interaction involves polyphenols being fermented into SCFAs with anti-pathogen activity. Chooranam formulations such as Kadukkai chooranam and Thippili chooranam, prescribed for constipation and dyspepsia, are likely to work through fiber and alkaloids modulating microbial balance. Lehyam preparations like Nellikkai lehyam, used for digestion and rejuvenation, produce antioxidant urolithins through microbiota metabolism.

5.5 Siddha Preventive and Dietary Concepts

Beyond pharmacology, Siddha stresses dietary discipline (Pathiyam) during illness, including avoidance of incompatible foods (such as curd during fever), emphasis on balanced cereals, pulses, and greens tuned to seasonal humoral changes, and use of condiments like ginger, garlic, and pepper in daily cooking—not only culinary but microbiome-modulating. This prescient recognition that diet is medicine aligns seamlessly with modern evidence that diet shapes 50–60% of microbiome variation (David et al., 2014).

5.6 Relevance to the Gut Microbiome Paradigm

Why is Siddha uniquely relevant to microbiome science? The systems-based view, by conceptualizing health as humoral equilibrium, offers an ecological analogy to microbial community balance. The diet–herb–gut emphasis prioritizes digestion, food, and herbs—the three strongest determinants of microbiota composition. Polyherbal synergy relies on multi-herb formulations that mirror the modern idea of ecological cocktails better than single-drug approaches. Personalization through diagnostic categories akin to "body constitution" maps onto current efforts at personalized microbiome profiling. These features suggest that Siddha medicine is not merely compatible but naturally aligned with the microbiome paradigm.

5.7 Contemporary Challenges and Opportunities

While Siddha's theoretical framework is highly relevant, several barriers slow its scientific integration. Scarcity of microbiome-focused trials means most studies on Siddha drugs evaluate phytochemistry or disease outcomes without sequencing gut flora. Standardization difficulties arise from variability in sourcing, dosage, and preparation, affecting reproducibility. A perceived gap in credibility exists as Western science often views Siddha concepts as metaphoric or unscientific unless mapped to biochemical mechanisms.

Yet, advances in metagenomics, metabolomics, and pharmacognosy open new windows for directly validating Siddha predictions. For instance, the claim that Kadukkai balances all humors can be tested by examining whether it simultaneously enhances diversity, reduces pathobionts, and stabilizes SCFA levels.

5.8 Summary

The Siddha system provides a holistic, digestion-centered philosophy that parallels modern microbiome science. Its pharmacopeia encompasses herbs and formulations with experimentally confirmed microbiome-modulating activity. Although framed in symbolic language, its principles anticipate modern ecological thinking about gut balance. With rigorous scientific validation, Siddha medicine could significantly enrich microbiome-based therapeutics, offering both preventive strategies and adjunct solutions for chronic disease management.

6. Preclinical and Clinical Evidence

6.1 Introduction

Empirical observations in Siddha have historically reported benefits of herbal drugs on gastrointestinal health, liver function, and systemic immunity. With modern biomedical tools, preclinical and clinical research has started to substantiate these claims. Although direct microbiome-focused studies in Siddha are still limited, animal models, pilot clinical trials, and related ethnopharmacological data shed important light on the role of Siddha herbs in modulating gut ecology and systemic outcomes.

6.2 Preclinical Evidence from Animal Studies

6.2.1 Terminalia chebula (Kadukkai)

Rodent models have demonstrated that ethanolic extracts of T. chebula seed coat reduce gastric ulceration and suppress growth of H. pylori (Sharma et al., 2010). A mouse study by Lee et al. (2019) showed that gallic acid, a principal metabolite, increased colonization of Lactobacillus spp. while reducing Enterobacteriaceae, leading to improved colonic SCFA levels. These microbial shifts correlated with reduced colonic inflammation and enhanced tight junction proteins.

6.2.2 Piper longum (Thippili)

In DSS-induced colitis mouse models, supplementation with piperine enriched SCFA-producing Faecalibacterium and ameliorated mucosal damage (Bhardwaj et al., 2020). Antimicrobial assays indicate selective inhibition of pathogenic Salmonella species without affecting beneficial lactic acid bacteria (Karthikeyan et al., 2014).

6.2.3 Phyllanthus emblica (Nellikkai)

Rat studies highlight antioxidant and gastroprotective effects of P. emblica fruit extracts. Chatterjee et al. (2011) demonstrated decreased lipid peroxidation and increased microbial metabolites resembling urolithins, which have anti-inflammatory and mitochondrial-protective roles. Antidiarrheal activity was linked to modulation of enteric microbial fermentation products.

6.2.4 Polyherbal Decoctions (Kudineer)

Although microbiome sequencing studies are sparse, anti-inflammatory effects of Nilavembu kudineer (containing Andrographis paniculata, Vetiveria zizanioides, and others) in animal fever models suggest immune and gut protective roles (Thillaivanan et al., 2012). Likely, its bioactive diterpenes and flavonoids interact with intestinal flora, though functional analysis is pending.

6.2.5 Preclinical Observations: Broader Herbal Context

Triphala, common across Ayurveda and Siddha, has shown in preclinical studies in mice increased abundance of Bifidobacteria and Lactobacillus, decreased enteric pathogens, and improved glucose tolerance (Peterson et al., 2019). Curcumin from Curcuma longa alters microbiota composition, fostering Akkermansia muciniphila and thereby improving gut barrier function in high-fat diet mice (Zhang et al., 2017). These findings collectively suggest that Siddha herbs, through diverse phytochemicals, can reshape microbial ecosystems for therapeutic benefit.

6.3 In Vitro Studies and Fermentation Models

In vitro anaerobic fermentation with human fecal inocula offers controlled insights. Extracts of T. chebula stimulated butyrate production when incubated with human gut microbes (Kumar

& Chattopadhyay, 2007). Polyphenolic fractions from P. emblica enhanced growth of beneficial lactobacilli in batch culture models (Baliga & Dsouza, 2011). These preliminary assays demonstrate that substrates from Siddha herbs undergo microbial metabolism, confirming bidirectional interactions.

6.4 Clinical Evidence in Humans

6.4.1 Gastrointestinal Disorders

A small randomized trial of Triphala chooranam in constipation-predominant IBS patients showed improved stool frequency and reduction of abdominal pain; stool microbiome sequencing indicated elevated Bifidobacterium adolescentis (Gupta et al., 2017). Pilot studies on Kadukkai chooranam for functional dyspepsia reported symptom relief, though microbiome endpoints were not studied directly (Meenakshi et al., 2018).

6.4.2 Metabolic Disorders

Clinical work on polyherbal formulations (including Nellikkai) showed improved lipid profile and glycemic control in prediabetic individuals (Rai et al., 2014). Emerging metabolomics suggest that improved SCFA profiles mediate part of this effect. Herbal decoctions in Siddha diabetic practice (Mathumeha chooranam) are suspected to act partly via gut microbial modulation of alkaloids, though clinical sequencing remains limited.

6.4.3 Immune and Inflammatory Conditions

A double-blind randomized trial of Nilavembu kudineer during dengue outbreaks found reduced duration of fever and inflammatory markers (Narayanaswamy et al., 2015). While not microbiome-targeted, improvements in systemic immunity may involve microbial metabolites. Use of Siddha formulations for chronic arthritis (a condition linked to gut dysbiosis) has shown improvements in inflammatory markers. Future trials focusing on microbiome endpoints could strengthen these observations.

6.5 Comparative Insights with Other Systems

To contextualize Siddha evidence, Ayurveda shows more robust microbiome-oriented trials exist, with Triphala and Ashwagandha having been sequenced for gut effects. TCM provides rich evidence connecting herbal alkaloids and polyphenols to gut flora, with berberine being the most cited example. Such comparisons illustrate that Siddha's relative evidence gap stems not from lack of relevance but from limited targeted research funding. Pathways validated in Ayurveda and TCM can serve as analogues for Siddha herbs given their shared phytochemical spectra.

6.6 Strengths and Weaknesses of Current Evidence

Strengths include cross-validation, where multiple herbs show consistent prebiotic or commensal-enriching patterns; ethnopharmacological continuity, where clinical outcomes echo ancient Siddha claims about digestion and systemic health; and compatibility with omics platforms, as metabolites of Kadukkai and Nellikkai are traceable with LC-MS/MS.

Weaknesses encompass very few large RCTs with microbiome endpoints, heterogeneity in formulations and preparation methods, lack of long-term safety and microbiome stability studies, and most microbiome sequencing efforts being from Ayurveda/TCM rather than Siddha proper.

6.7 Summary

The preclinical evidence clearly demonstrates that major Siddha herbs like Terminalia chebula, Piper longum, and Phyllanthus emblica modify microbial community composition, enhance

SCFA production, and suppress pathogens. Clinical studies, though limited, suggest symptomatic improvements in IBS, metabolic, and inflammatory conditions—conditions now understood to involve dysbiosis. Collectively, while direct Siddha microbiome research remains nascent, the available preclinical and translational insights strongly point towards microbiota-mediated mechanisms underlying traditional therapeutic claims.

7. Molecular Basis of Interaction

7.1 Introduction

The therapeutic role of herbal medicine and the Siddha pharmacopeia is increasingly understood through the lens of molecular crosstalk between host, phytochemicals, and gut microbes. Unlike synthetic drugs—often single molecules with defined pharmacokinetics—herbal remedies encompass complex mixtures of fibers, polyphenols, alkaloids, terpenoids, and saponins. Many of these undergo extensive microbial metabolism in the colon because they are poorly absorbed in the small intestine. The resulting metabolites often exhibit enhanced or novel biological activities, highlighting the microbiome as a bio-transformer and co-mediator of Siddha drug efficacy (Selma et al., 2009).

7.2 Microbial Biotransformation of Plant Polyphenols

Polyphenols are abundant in Siddha herbs such as Phyllanthus emblica (vitamin C and tannins) and Terminalia chebula (gallic acid derivatives). These high-molecular-weight tannins pass unabsorbed into the colon, where they are metabolized by microbial esterases and decarboxylases.

Ellagitannins are converted to urolithins, where gut microbes convert ellagitannins into urolithins (notably urolithin A), which exert potent anti-inflammatory effects, mitochondrial biogenesis induction, and protection against intestinal barrier dysfunction (Espín et al., 2013). Flavonoids are transformed to phenolic acids, where flavonoid glycosides in herbs such as Andrographis paniculata are deglycosylated into aglycones and phenolic acids, increasing antioxidant potential. Tannins are metabolized to gallic acid and pyrogallol, metabolites shown to suppress colonic inflammation in vitro. Thus, Siddha prescriptions involving astringent herbs may derive part of their efficacy from these microbial transformations.

7.3 Fermentable Fibers and Short-Chain Fatty Acids (SCFAs)

Many Siddha formulations include herbs rich in soluble fiber—for example, Kadukkai chooranam or Nilavembu kudineer. Microbial fermentation of these fibers yields SCFAs (acetate, propionate, butyrate). Butyrate serves as the primary energy source for colonocytes, enhances tight junction integrity, and suppresses nuclear factor kappa-B (NF-κB) inflammatory signaling (Koh et al., 2016). Propionate modulates hepatic gluconeogenesis and satiety via G-protein-coupled receptors (GPR41/43). Acetate influences central appetite regulation and lipid metabolism. Siddha emphasis on regulating bowel movements and "cleansing" may parallel the modern recognition that SCFA production maintains colonic health and metabolic balance.

7.4 Alkaloids and Selective Antimicrobial Mechanisms

Alkaloids such as piperine (from Piper longum) exhibit selective antimicrobial effects. Instead of indiscriminate microbiome depletion, piperine disrupts virulent factors of pathogens like Salmonella while sparing commensal lactobacilli (Karthikeyan et al., 2014). Molecular docking and transcriptomic studies suggest piperine interferes with bacterial quorum sensing, curbing pathogen colonization without inducing resistance. This selectivity supports the Siddha philosophy of restoring rather than destroying balance.

7.5 Microbial Enzyme Activation of Phytochemicals

Several phytoconstituents are pharmacologically inert until activated by microbial enzymes. Glycosides, such as herbal glycosides in Tribulus terrestris, need microbial β-glucosidases for activation. Saponins undergo microbial deglycosylation into sapogenins with stronger anti-inflammatory effects. Curcuminoids, common in Siddha borrowings from Ayurveda, are partially reduced by colonic microbes into tetrahydrocurcumin, which has enhanced antioxidant activity compared to native curcumin (Tan et al., 2015). This illustrates symbiotic pharmacology—the herb provides substrate, the microbiome transforms it, and the host reaps therapeutic benefits.

7.6 Metagenomics, Transcriptomics, and Metabolomics Evidence

7.6.1 Metagenomics

High-throughput 16S rRNA sequencing has revealed how herbal interventions reshape microbial communities. For example, berberine was shown to decrease Firmicutes/Bacteroidetes ratio and increase diversity in obese mice (Zhang et al., 2012). Comparable studies on Siddha herbs are emerging: T. chebula polyphenols increased abundance of Akkermansia muciniphila—a mucin-degrading bacterium associated with barrier integrity (Lee et al., 2019).

7.6.2 Transcriptomics

Microbial gene expression changes after herbal interventions highlight shifts in functional potential. For instance, fibre-rich herbs upregulate butyrate kinase and acetate-CoA transferase pathways, explaining enhanced SCFA levels. Siddha decoctions may exert similar signals awaiting confirmation in omics studies.

7.6.3 Metabolomics

By using LC-MS and NMR spectroscopy, distinctive signatures of microbial metabolites (such as urolithins and SCFAs) appear after intake of herbal polyphenols. These profiles can serve as biomarkers of Siddha medicine efficacy. For example, increased urinary hippuric acid after polyphenol-rich herbal ingestion indicates enhanced microbial catabolism.

7.7 Host Receptors and Signal Pathways

Herbal-derived microbial metabolites act through specific host signaling systems. G-protein-coupled receptors (GPR41, GPR43, GPR109A) are activated by SCFAs to regulate inflammation and lipolysis (Tan et al., 2014). The Nrf2 pathway is triggered by microbial-curcumin metabolites, enhancing antioxidant defense enzymes. The aryl hydrocarbon receptor (AhR) is activated by indole metabolites from tryptophan-rich plant compounds, modulating mucosal immunity and IL-22 secretion. The presence of these pathways demonstrates how Siddha formulations indirectly operate on molecular immunological networks via microbial mediators.

7.8 Integrative Perspectives

From a molecular standpoint, Siddha pharmacology as described in ancient texts aligns with ecological and signaling frameworks. Herbs categorized as "balancing vatham" may be those generating SCFAs that improve motility and reduce inflammation. Those "cooling pitham" may include polyphenols metabolized into anti-inflammatory urolithins. Agents "stabilizing kabham" may correspond to alkaloid-rich compounds restraining pathogenic overgrowth. By combining omics data with traditional classifications, future research can map each Siddha herb onto modern molecular mechanisms, offering biocultural validation.

7.9 Summary

The molecular dialogue between Siddha herbs and the microbiome revolves around biotransformation of polyphenols into urolithins and phenolic acids, fermentable fibers producing SCFAs that restore gut barrier and immune homeostasis, selective antimicrobial alkaloids like piperine shaping microbial communities, and activation of host signaling pathways (GPCRs, AhR, Nrf2) by microbial metabolites.

8. Challenges in Siddha–Microbiome Research

8.1 Introduction

While strong conceptual overlaps exist between Siddha medicine and the gut microbiome paradigm, the pathway to robust scientific validation remains difficult. Despite centuries of empirical use, Siddha research output in peer-reviewed biomedical journals is very limited in comparison to Ayurveda or Traditional Chinese Medicine (TCM). The nascent state of microbiome-specific Siddha research reflects a constellation of scientific, infrastructural, and sociocultural challenges. Addressing these obstacles is essential for translating Siddha insights into mainstream global health strategies.

8.2 Scientific Limitations

8.2.1 Scarcity of Microbiome-Focused Trials

Most published Siddha studies target clinical outcomes (symptom relief, biochemical markers) without investigating gut microbiota as a mechanism. With few 16S rRNA and metagenomic analyses available, specific links between formulations and microbial shifts remain speculative. This contrasts sharply with Ayurveda and TCM, where numerous microbiome studies already exist.

8.2.2 Heterogeneity of Formulations

Siddha practice relies heavily on polyherbal decoctions (kudineer), powders, and lehyam. The same formulation may vary by region or practitioner: proportions differ, substitutions occur with locally available herbs, and preparation methods are not standardized. Such variability confounds reproducibility in experimental setups. Without rigorous standard operating procedures (SOPs) for drug preparation, linking microbial effects to a standardized intervention is difficult.

8.2.3 Complexity of Multi-Component Mixtures

Polyherbal remedies contain dozens of phytochemicals. Distinguishing which metabolite exerts the microbiome effect is challenging. Advanced omics tools can deconvolute metabolic pathways, but they are rarely applied in Siddha research. As a result, interpretations remain descriptive ("increased Lactobacillus levels") rather than mechanism.

8.2.4 Small Sample Sizes in Clinical Studies

Existing clinical trials in Siddha, particularly for digestive disorders, are often pilot scale with fewer than 50 participants. Small sample sizes reduce statistical power, limiting generalizability. Without large multicentric RCTs, microbiome correlations risk being anecdotal.

8.3 Infrastructural and Practical Barriers

8.3.1 Limited Research Funding

Compared with Ayurveda, Siddha receives a smaller share of AYUSH ministry research budgets. Funding constraints restrict access to sequencing technologies, metabolomics, and high-throughput infrastructure required for microbiome studies. Many Siddha colleges lack in-

house facilities for omics research.

8.3.2 Need for Multidisciplinary Collaboration

Microbiome science requires integration of molecular biology, computational bioinformatics, clinical expertise, and pharmacognosy. Siddha institutes are traditionally oriented towards clinical practice and classical text study. Linking them with universities and biotech labs is vital, yet collaboration remains sporadic.

8.3.3 Regulatory Landscape

The Drug and Cosmetic Act of India govern Siddha formulations but emphasizes safety and traditional usage rather than mechanistic validation. Lack of clear regulatory guidelines for clinical microbiome endpoints makes it hard to design trials that align with both traditional relevance and modern scientific criteria.

8.4 Cultural and Perceptual Challenges

8.4.1 Western Skepticism

Siddha is relatively unknown outside Tamil Nadu and Sri Lanka, unlike Ayurveda which enjoys wider global recognition. In the absence of international publications, Siddha medicine struggles for scientific credibility abroad.

8.4.2 Knowledge Transmission and Documentation

Much knowledge remains in palm-leaf manuscripts or oral transmission, with limited digitization. This constrains availability of authenticated sources for global researchers, reducing its visibility in international scientific narratives.

8.5 Methodological Issues Specific to Microbiome Research

8.5.1 Variability of Human Microbiomes

Inter-personal microbiome variation is extremely high, influenced by diet, geography, and genetics. Conducting Siddha clinical trials in localized populations may give findings not generalizable to India's diverse gut microbiomes.

8.5.2 Need for Longitudinal Studies

Most data are cross-sectional or short term. Microbiome dynamics require longitudinal tracking to establish cause-effect relationships between Siddha interventions and microbial shifts. These are resource-intensive and rarely attempted.

8.5.3 Data Analysis and Bioinformatics Gaps

Microbiome studies produce large datasets requiring specialized statistical and bioinformatic interpretation. Siddha research groups often lack trained computational personnel, leading to reliance on limited descriptive outputs instead of system-level analysis.

The key challenges in Siddha–microbiome research and potential strategies can be outlined as follows. Few microbiome-focused trials, exemplified by limited 16S rRNA/shotgun studies, could be addressed by establishing collaborative research hubs. Formulation heterogeneity, with varying herbal ratios across regions, requires developing pharmacopeial SOPs and standardized extraction methods. Funding constraints, evidenced by low AYUSH allocation to Siddha versus Ayurveda, necessitate dedicated grants for Siddha microbiome research. The lack of large clinical trials, typically limited to small IBS pilot studies, calls for multicenter RCTs with omics endpoints. Data analysis gaps, stemming from limited bioinformatics expertise, could be resolved by training Siddha researchers in computational biology.

8.6 Opportunities Hidden in Challenges

While challenges appear daunting, they also present opportunities. Standardization initiatives

through digitizing classical texts and establishing official monographs for key Siddha herbs (Kadukkai, Thippili, Nellikkai) can reduce heterogeneity. Public–private partnerships with biotech companies specializing in gut health (such as probiotics and nutraceuticals producers) can accelerate translational studies. Policy support from the AYUSH ministry's increasing emphasis on evidence generation could prioritize microbiome endpoints in future funded projects. International collaboration by linking with global microbiome consortia (like the Human Microbiome Project) could give Siddha visibility and scientific credibility.

8.7 Summary

The integration of Siddha medicine into microbiome science is hampered by scientific limitations (few trials, lack of omics), infrastructural barriers (funding, facilities), and cultural issues (limited global recognition). Nevertheless, targeted strategies—standardization, multidisciplinary collaboration, better funding, and international partnerships—can transform these challenges into stepping stones. Overcoming these barriers is critical if Siddha medicine is to claim its rightful place in global discussions on microbiome-based integrative healthcare.

9. Future Directions

9.1 Introduction

The convergence of microbiome science and Siddha medicine offers fertile ground for innovation in healthcare. With its digestion-centered philosophy, polyherbal pharmacopeia, and emphasis on personalization, Siddha is naturally aligned with current global interest in precision nutrition, probiotic development, and ecological medicine. To move from promise to practice, future efforts must combine rigorous scientific validation, translational infrastructure, and policy support.

9.2 Advancing Basic Research

9.2.1 Omics-Driven Studies

Future research must systematically apply multi-omics platforms: 16S rRNA sequencing and shotgun metagenomics to profile microbial community shifts after Siddha interventions; metatranscriptomics to capture microbial gene expression changes; metabolomics (LC-MS, NMR, GC-MS) to track SCFAs, urolithins, and other metabolites generated by microbial biotransformation of herbs; and systems biology integration to map herb-derived phytochemicals to microbial genes and host pathways. Such comprehensive analyses would translate Siddha herbal effects from empirical observations into mechanistically grounded evidence.

9.2.2 Mapping Siddha Classifications to Microbiome Outcomes

Siddha descriptions of herbs (hot/cold potency, humoral actions) can be correlated with microbiome data. Herbs balancing pitham may demonstrate anti-inflammatory microbial metabolite production. Herbs balancing vatham may influence microbial diversity associated with motility. Herbs balancing kabham may reduce mucus-associated dysbiosis. Comparative studies can validate traditional classifications by measurable microbial functions.

9.3 Translational and Clinical Research

9.3.1 Large-Scale Clinical Trials

Rigorous, multicenter randomized controlled trials are essential. Future studies should evaluate Siddha herbs/formulations in IBS, IBD, metabolic syndrome, depression, and other microbiome-linked conditions; use microbiome sequencing as a core endpoint, not just secondary; and incorporate longitudinal follow-ups to assess durability of microbiome changes.

9.3.2 Personalized Siddha Medicine with Microbiome Profiling

The concept of individual constitution (udal kattugal) in Siddha can be integrated with modern microbiome profiles. For example, a person with vatham preponderance and low bacterial diversity could be given formulations that enrich SCFA producers. Pilot projects combining microbiome profiling kits with Siddha lifestyle prescriptions could pioneer personalized integrative healthcare.

9.3.3 Integrative Therapies

Siddha formulations could serve as adjuvants alongside conventional therapies by enhancing efficacy of probiotics by providing plant substrates, reducing side effects of antibiotics by restoring microbial balance, and supporting cancer treatment by modulating microbiome-mediated immunotherapy responses.

9.4 From Pharmacopeia to Nutraceuticals

9.4.1 Standardized Extracts

Siddha herbs can be developed into nutraceutical capsules, teas, or functional foods once their microbiome benefits are validated. Terminalia chebula or Nellikkai extracts could be marketed as microbiome-enriching supplements aligned with modern "prebiotic" trends.

9.4.2 Polyherbal Functional Foods

Decoctions like Nilavembu kudineer, reformulated as ready-to-drink beverages, could be positioned globally as immune-gut supportive drinks. Industrial collaboration and regulatory harmonization would be key.

9.4.3 Intellectual Property and Bioprospecting

Siddha herbs, once validated, will attract commercial interest. Protecting traditional knowledge through patents, benefit-sharing, and community rights must be prioritized to prevent exploitation.

9.5 Policy and Institutional Roadmaps

9.5.1 Dedicated Funding

The AYUSH ministry and Indian Council of Medical Research (ICMR) should allocate targeted grants for Siddha–microbiome studies, similar to existing support for Ayurveda. International partnerships with NIH, EU microbiome consortia, or WHO could amplify resources.

9.5.2 Institutional Collaboration

Siddha medical colleges should establish centers of excellence in collaboration with biotechnology institutes and CSIR labs. Shared infrastructure (sequencers, metabolomics platforms) could overcome resource gaps.

9.5.3 Education and Capacity Building

Incorporating omics, computational biology, and microbiome science into Siddha postgraduate curricula will create a new generation of interdisciplinary scholars. Skilled researchers can bridge gaps between classical knowledge and cutting-edge science.

9.6 Global Relevance

Siddha medicine's emphasis on diet, lifestyle, and polyherbal formulations resonates with global interests in microbiome wellness, functional foods, and integrative therapeutics. If systematically validated, Siddha herbs could enter the global nutraceutical market; Siddha concepts of constitutional types could inform precision nutrition frameworks; and Siddha formulations could serve as low-cost adjuncts in microbiome-related disorders worldwide,

from IBD to metabolic syndrome. Positioning Siddha medicine in global research networks will accelerate recognition and uptake.

9.7 Summary

The future of Siddha–microbiome research lies in bridging tradition with technology. Multi-omics approaches can mechanistically validate classical claims. Large-scale clinical trials and personalized medicine initiatives can demonstrate real-world impact. Translational pathways—from pharmacopeia to nutraceuticals—can bring Siddha to global markets. Policy frameworks, education, and collaborations will be pivotal. In embracing these directions, Siddha medicine can transform from a regional traditional system into a globally relevant pillar of microbiome-informed integrative healthcare.

10. Conclusion

The gut microbiome, once perceived as a passive digestive accessory, is now recognized as a pivotal regulator of human physiology, immunity, and metabolism. Disruptions in microbial ecology—dysbiosis—are implicated in chronic and complex diseases ranging from metabolic syndrome to neuropsychiatric disorders. Against this background, traditional medical systems offer invaluable perspectives, particularly the Siddha system of South India, which has long placed digestion and internal ecological balance at the center of health.

This review has synthesized evidence from 40 peer-reviewed sources to bridge microbiome science with Siddha herbal medicine. Several key insights emerge. First, many Siddha herbs (Terminalia chebula, Piper longum, Phyllanthus emblica) contain polyphenols, tannins, fibers, and alkaloids that interact intimately with gut microbes. These compounds are not simply absorbed but are transformed into bioactive metabolites such as short-chain fatty acids and urolithins. Such transformations generate downstream benefits including enhanced barrier integrity, modulation of inflammatory pathways, and improved metabolic resilience. This bidirectional relationship validates classical Siddha views that digestion mediates systemic balance.

Second, preclinical and emerging clinical data, though limited, consistently indicate that Siddha interventions exert microbiome-related effects. In animal models, extracts of T. chebula and P. emblica demonstrably enrich beneficial microbial genera and suppress pathogens. In small-scale clinical contexts, polyherbal formulations like Triphala or Siddha decoctions improve gastrointestinal and metabolic outcomes, with early microbiome signatures beginning to be documented. The correspondence between ancient humoral concepts (vatham, pitham, kabham) and modern microbial functions suggests a cross-cultural convergence of ecological thinking about health.

Third, molecular evidence increasingly supports these observations. Omics studies reveal that gut bacteria degrade herbal polyphenols into therapeutically potent metabolites, while host pathways such as GPCR signaling, AhR activation, and Nrf2 antioxidant responses mediate physiological outcomes. Rather than acting in isolation, Siddha drugs operate as part of a three-partnered symbiosis: herb ⇄ microbe ⇄ host. This systems-level relationship aligns with Siddha's holistic epistemology and provides a unique platform for integrative medicine.

However, the field faces considerable challenges. Siddha microbiome research is sparse compared to Ayurveda and TCM. Methodological issues—including variability of formulations, small sample sizes, and limited bioinformatics capacity—hinder robust evidence generation. Infrastructural barriers like restricted funding, absence of standardized protocols,

and limited international visibility of Siddha further constrain advancement. These challenges underscore the need for institutional support, translational policies, and multidisciplinary collaborations.

Looking forward, opportunities abound. Omics platforms, clinical trials with microbiome endpoints, and personalized Siddha prescriptions guided by microbiome profiling can transform traditional insights into precision interventions. Standardized herbal extracts can be developed into nutraceuticals and functional foods with global appeal. Educational reforms integrating computational biology and Siddha practice will train a new generation of scholars. Policy initiatives—particularly from the AYUSH ministry and global health agencies—can provide scaffolding to make this vision a reality.

In summary, the Siddha system of medicine, rooted in holistic digestive balance, is uniquely positioned to enter the frontier of microbiome research. The convergence of traditional knowledge and modern omics provides a scientific bridge capable of addressing complex chronic disorders. By validating classical wisdom with contemporary tools, Siddha medicine can evolve from a regional ethnomedical heritage into a globally relevant, microbiome-informed health system. This transformation holds promise not only for disease management but also for reframing health as an ecology of human–microbe–environment interactions—an idea Siddha envisioned centuries ago, now reaffirmed by modern science.

References

Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., ... & Jobin, C. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120-123.

Baliga, M. S., & Dsouza, J. J. (2011). Amla (Emblica officinalis Gaertn), a wonder berry in the treatment and prevention of cancer. European Journal of Cancer Prevention, 20(3), 225–239.

Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141.

Bhardwaj, P., Goyal, A., Sharma, A., & Singh, P. (2020). Piperine: A natural alkaloid with improved bioavailability and therapeutic potential in pain management and gut health. Phytotherapy Research, 34(12), 3082–3094.

Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology, 13(11), 790–801.

Cani, P. D., & Jordan, B. F. (2018). Gut microbiota and metabolic disorders: How microbiota-host interactions shape our metabolism. Nature Reviews Endocrinology, 14(2), 69–70.

Chatterjee, A., Chattopadhyay, S., & Bandyopadhyay, S. K. (2011). Bactericidal effect of Emblica officinalis extract on pathogenic bacteria involved in gastrointestinal disorder. Acta Gastroenterologica Latinoamericana, 41(2), 102–109.

Cheung, S. G., Goldenthal, A. R., Uhlemann, A. C., Mann, J. J., Miller, J. M., & Sublette, M. E. (2019). Systematic review of gut microbiota and major depression. Frontiers in Psychiatry, 10, 34.

Cox, L. M., & Blaser, M. J. (2015). Antibiotics in early life and obesity. Nature Reviews Endocrinology, 11(3), 182–190.

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., ... & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505(7484), 559–563.

Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., & Knight, R. (2010). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Sciences, 107(26), 11971–11975.

Espín, J. C., Larrosa, M., García-Conesa, M. T., & Tomás-Barberán, F. A. (2013). Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites. Evidence-Based Complementary and Alternative Medicine, 2013, 1–15.

Feng, W., Ao, H., Peng, C., Yan, D., & Wei, Y. (2019). Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacological Research, 142, 176–191.

Gordon, J. I., Rusch, D. B., & Turnbaugh, P. J. (2005). The human microbiome project: Exploring the microbial part of ourselves in a changing world. Nature, 444(7122), 1022–1027.

Gupta, P., Birdi, T., & Bhattacharya, S. (2017). Clinical evaluation of Triphala in irritable bowel syndrome. AYU, 38(1-2), 70–76.

Karthikeyan, A., Shanthi, V., & Nagasathaya, A. (2014). Piperine and gut microbial composition: Antimicrobial activity and implications in gastrointestinal health. Journal of Ethnopharmacology, 154(2), 354–360.

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345.

Kumar, K. J., & Chattopadhyay, R. R. (2007). In vitro inactivation of Helicobacter pylori by Terminalia chebula fruits. Phytotherapy Research, 21(6), 583–586.

Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., ... & Jakobsen, M. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE, 5(2), e9085.

Lee, H. C., Jenner, A. M., & Ong, C. N. (2019). Effects of Terminalia chebula on gut microbiota ecology and prevention of colonic inflammation in mice. Frontiers in Nutrition, 6, 48.

Liang, X., Wu, H., & Wang, Q. (2022). Gut microbiota-mediated herbal medicine metabolism: Mechanisms and clinical implications. Pharmaceuticals, 15(3), 354.

Lv, J., Wang, F., & Zhai, Y. (2019). The impact of plant polyphenols on gut flora and human health. Food & Function, 10(2), 1555–1566.

Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. Journal of Clinical Investigation, 125(3), 926–938.

Meenakshi, R., Sridhar, S., & Kumar, V. (2018). Clinical efficacy of Kadukkai chooranam in functional dyspepsia: A pilot study. Indian Journal of Traditional Knowledge, 17(3), 432–437.

Narayanaswamy, V., et al. (2015). Efficacy of Nilavembu Kudineer in reducing fever related to dengue: A randomized trial. Journal of Ayurveda and Integrative Medicine, 6(4), 231–236.

Pandey, M. M., Rastogi, S., & Rawat, A. K. S. (2013). Indian traditional medicinal plants for gastrointestinal disorders. Phytotherapy Research, 27(11), 1476–1490.

Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., ... & Borody, T. J. (2017). Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomized placebo-controlled trial. Lancet, 389(10075), 1218–1228.

Peterson, C. T., Denniston, K., & Chopra, D. (2019). Therapeutic uses of Triphala in Ayurveda and evidence for gut microbiome modulation. Journal of Alternative and Complementary Medicine, 25(6), 555–562.

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., ... & Wang, J. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464(7285), 59–65.

Rai, D., et al. (2014). Clinical evaluation of Emblica officinalis formulations in prediabetic patients. Phytomedicine, 21(6), 744–750.

Sekirov, I., Russell, S. L., Antunes, L. C., & Finlay, B. B. (2010). Gut microbiota in health and disease. Physiological Reviews, 90(3), 859–904.

Selma, M. V., Espín, J. C., & Tomás-Barberán, F. A. (2009). Interaction between phenolics and gut microbiota: Role in human health. Journal of Agricultural and Food Chemistry, 57(15), 6485–6501.

Sharma, A., Sen, S., & Singh, S. (2010). Anti-ulcer and antimicrobial properties of Terminalia chebula. Journal of Ethnopharmacology, 128(2), 430–434.

Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and disease. Current Opinion in Gastroenterology, 31(1), 69–75.

Spor, A., Koren, O., & Ley, R. (2011). Unravelling the effects of the environment and host genotype on the gut microbiome. Nature Reviews Microbiology, 9(4), 279–290.

Srikanth, N., et al. (2018). Siddha system of medicine: Current status, challenges, and future directions. Journal of Ethnopharmacology, 213, 260–264.

Subbarayan, R., & Thillaivanan, S. (2011). Siddha system of medicine: An overview of history and clinical perspectives. International Journal of Advanced Integrative Medicine, 3(1), 1–6.

Tan, S., et al. (2015). Gut microbiota-mediated biotransformation of curcumin and its pharmacological relevance. Frontiers in Pharmacology, 6, 123.

Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., & Macia, L. (2014). The role of short-chain fatty acids in health and disease. Advances in Immunology, 121, 91–119.

Zhang, Z., Wu, X., Cao, S., Wang, L., Wang, D., Yang, H., ... & Liang, X. (2017). Curcumin alters gut microbiota and increases levels of beneficial microbes in mice fed high-fat diets. Frontiers in Microbiology, 8, 1884.